News
Stifel Maintains Buy on Zymeworks, Raises Price Target to $21
2 Aug 24
News, Price Target, Analyst Ratings
Zymeworks Announces Share Repurchase Program Of Up To $60M Of Common Stock
1 Aug 24
News, Buybacks
Zymeworks Q2 2024 GAAP EPS $(0.49) Misses $0.07 Estimate, Sales $19.243M Miss $48.860M Estimate
1 Aug 24
Earnings, Earnings Misses, News
Zymeworks Says FDA Has Cleared Investigational New Drug Application For ZW191
22 Jul 24
News, FDA
Market-Moving News for June 17th
17 Jun 24
Movers, Trading Ideas
Zymeworks Achieves Key Milestone with BLA Acceptance for Zanidatamab in China, Zymeworks to Receive Up to $164M in Milestone Payments
10 Jun 24
Government, News, Regulations
Navigating 6 Analyst Ratings For Zymeworks
6 Jun 24
Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
6 Jun 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
1 Aug 24
News, Management, Press Releases
Zymeworks Announces Participation in Upcoming Investor Conferences
30 Jul 24
News, Press Releases
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
25 Jul 24
News, Management, Press Releases
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
22 Jul 24
Health Care, Press Releases, General
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
11 Jul 24
News, Press Releases
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
17 Jun 24
Health Care, Press Releases
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
10 Jun 24
Press Releases, General